Phenethanolamine derivatives with calorigenic and antidiabetic qualities

Area of Science:

• Pharmacology
• Metabolic Research
• Obesity and Diabetes Treatment

Background:

• Bis-phenethanolamine derivatives represent a new class of compounds with potential anti-obesity and antidiabetic properties.
• Obesity and type 2 diabetes are significant global health challenges requiring novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of p-[(R)-3-[bis-[(R)-beta-hydroxyphenethyl]amino]butyl]benzamide (Ro 16-8714) as a calorigenic agent.
• To investigate the anti-obesity and antidiabetic effects of Ro 16-8714 in animal models.

Main Methods:

• Assessed oxygen consumption and calorigenesis in normal and obese rodents.
• Investigated the role of beta-adrenoceptors in mediating the effects of Ro 16-8714.
• Evaluated brown adipose tissue (BAT) thermogenesis in vitro and in vivo.
• Monitored body weight, body fat, and body protein content during prolonged treatment.
• Assessed the impact on carbohydrate and fat oxidation.

Main Results:

• Ro 16-8714 demonstrated potent stimulation of oxygen consumption and calorigenesis, mediated by beta-adrenoceptors.
• The compound increased BAT thermogenesis and calorigenic capacity in obese rodents.
• Ro 16-8714 induced fat mobilization and oxidation in normal and obese rats.
• Antidiabetic effects were observed in obese mice, primarily through enhanced carbohydrate oxidation.
• Prolonged treatment led to reduced body weight gain and body fat content, while preserving body protein.

Conclusions:

• Ro 16-8714 exhibits significant anti-obesity and antidiabetic properties.
• The compound's mechanism involves enhanced thermogenesis, fat oxidation, and carbohydrate oxidation.
• Ro 16-8714 shows promise as a novel therapeutic agent for morbid obesity and maturity-onset diabetes.